Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
Abstract: The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
June 25, 2013
Assignee:
The Regents of the University of California
Inventors:
David Julius, David D. McKemy, Werner M. Neuhausser
Abstract: The invention relates to a method for determining the presence of an analyte by means of a distribution of small magnetic particles. According to said method, the magnetisations of the small particles are oriented in relation to each other by means of an outer magnetic focusing field; once the focussing field has been terminated, the magnetisations of the small particles are rotated asynchronously to the magnetic field by means of an outer magnetic field of suitable field intensity and rotational frequency, which rotates about a longitudinal axis (z); the temporal course of the superpositioned transverse magnetisation of the set of particles is detected; and the presence of the analyte is deduced from the detected temporal course. The invention also relates to a corresponding device (1).
Abstract: The invention relates to lipid bilayer coated beads and methods of using those beads in delivery systems, in immunoassays, in analytical assays and the like.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
June 18, 2013
Inventors:
Gabriel P. Lopez, Reema Zeineldin, Menake E. Piyasena, Sireesha Chemburu
Abstract: Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation.
Abstract: The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials.
Type:
Grant
Filed:
February 8, 2010
Date of Patent:
June 11, 2013
Assignee:
Accelerate Diagnostics, Inc.
Inventors:
David A. Goldberg, David C. Howson, Steven W. Metzger, Daniel A. Buttry, Steven Scott Saavedra
Abstract: The present invention relates, in general, to polypeptides having antigenic epitopes from granulocytic ehrlichia (GE) proteins and methods of use thereof.
Type:
Grant
Filed:
January 9, 2012
Date of Patent:
June 11, 2013
Assignee:
Antigenics, Inc.
Inventors:
Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
Type:
Grant
Filed:
June 9, 2010
Date of Patent:
June 11, 2013
Assignee:
Affitech Research AS
Inventors:
Lavinia Diana Cicortas Gunnarsson, Didrik Paus
Abstract: Arrays of single cells and methods of producing an array of single cells are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single cell capture, detection and quantitation.
Abstract: This novel form of multiplexing allows the user to probe for multiple targets and simultaneously identify a specific target. An example of solutions provided here comprises: providing one or more assay mixes for a number of targets (the number of assay mixes is less than the number of targets); providing a number of reference patterns (each of the reference patterns is associated with one of the targets); contacting each of a number of aliquots with one of the assay mixes; generating a result pattern, based on positive or negative results; and selecting the reference pattern most similar to the result pattern, to thereby detect the target. Differential multiplexing with pattern recognition may involve molecular or immunological techniques to identify one of many indicators of drug use, illness, disease, or medical condition.
Type:
Grant
Filed:
April 11, 2007
Date of Patent:
June 4, 2013
Assignee:
The United States of America as represented by the Secretary of the Air Force
Inventors:
Daniel H. Atchley, Craig T. Narasaki, John R. Hickman
Abstract: Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.
Type:
Grant
Filed:
July 30, 2009
Date of Patent:
June 4, 2013
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present invention relates to a method for the selective identification of Chlamydia trachomatis infections wherein the antigens CT017, CT098, CT318-L1 P, CT431-TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates the selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae. The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis-specific antigens for the identification of antibodies. The biochip with antigens according to the invention is suitable for multiparameter identification methods in particular.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
June 4, 2013
Assignee:
Mikrogen GmbH
Inventors:
Ulrike Simnacher, Vera Forsbach-Birk, Andreas Essig, Klaus-Ingmar Pfrepper
Abstract: The present invention provides a biosensor cartridge (11) comprising a bottom portion (1) with a well (2) adapted to accommodate a liquid sample and a cover portion (3) for closing said well (2). The well (2) has a sensor surface (4). The bottom portion (1) is adapted for allowing light to enter along a first optical path (5), to be reflected at the sensor surface (4) and to exit along a second optical path (6). The invention further relates to a method of manufacturing such a cartridge (11).
Abstract: The present invention relates to a structure comprising a biological membrane and a porous or perforated substrate, a biological membrane, a substrate, a high throughput screen, methods for production of the structure membrane and substrate, and a method for screening a large number of test compounds in a short period. More particularly it relates to a structure comprising a biological membrane adhered to a porous or perforated substrate, a biological membrane capable of adhering with high resistance seals to a substrate such as perforated glass and the ability to form sheets having predominantly an ion channel or transporter of interest, a high throughput screen for determining the effect of test compounds on ion channel or transporter activity, methods for manufacture of the structure, membrane and substrate, and a method for monitoring ion channel or transporter activity in a membrane.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
May 28, 2013
Assignee:
Xention Limited
Inventors:
David Geraint Owen, Nicholas Gerard Byrne
Abstract: The invention provides a screening method and screening kit for a cell protecting agent. Specifically, the invention provides a method for screening a cell protecting agent showing an Hsp90-binding activity and a heat shock protein expression-inducing activity but having no Hsp90 client protein degradation-promoting activity. The method comprises the following steps (1) to (3): (1) measuring the binding property of a test compound to Hsp90; (2) measuring the activity of a test compound to induce the expression of a heat shock protein, or measuring the activity of a test compound to disrupt an Hsp90/HSF-1 complex, by using a cell capable of expressing the heat shock protein; and (3) measuring the activity of a test compound to induce the degradation of an Hsp90 client protein by using a cell capable of expressing the Hsp90 client protein.
Abstract: A method of filtering a liquid sample that includes passing a sample comprising at least one biological organism through a filter membrane at a water volume flux of at least 100 L/m2.h.psi, where the filter membrane comprises a Bubble Point pore size of no more than 1.0 ?m and where at least one biological organism is retained on the surface of the membrane. The method further includes detecting the at least one biological organism retained on the surface of the filter membrane.
Type:
Application
Filed:
June 6, 2011
Publication date:
May 23, 2013
Inventors:
Raj Rajagopal, Wensheng Xia, Jinsheng Zhou, James E. Aysta, Guoping Mao
Abstract: The present invention relates to a method for detecting and quantifying an analyte present in a liquid of interest using a solid support, the surface of which comprises at least one active area on which at least one probe capable of binding said analyte is immobilized and a solution containing at least one secondary reagent capable of binding to the analyte, said method comprising a step consisting of recycling said solution in order to put it back into contact with the surface and notably with the active area at least one additional time. The present invention also relates to a device which may be applied within the scope of such a method.
Type:
Application
Filed:
April 22, 2011
Publication date:
May 23, 2013
Applicant:
Commissariat a L'Energie Atomique ET Aux Energies Alternatives
Abstract: Disclosed are methods, systems, and apparatuses for the free solution measurement of molecular interactions by backscattering interferometry (BSI). Molecular interaction can be detected between analytes in free-solution wherein at least one of the analytes is label-free and detection is performed by back-scattering interferometry. Further, molecular interaction can be detected between analytes in free-solution, wherein at least one of the analytes is label-free, wherein one of the analytes is present in a concentration of less than about 5.0×10?7M. Also disclosed are label-free, free-solution, and/or real-time measurements of characteristic properties and/or chemical events using the disclosed techniques. The disclosed methods can have very low detection limits and/or very low sample volume requirements. Also disclosed are various biosensor applications of the disclosed techniques.
Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
Type:
Grant
Filed:
May 2, 2011
Date of Patent:
May 21, 2013
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Jerome W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
Abstract: The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers.
Type:
Grant
Filed:
September 3, 2009
Date of Patent:
May 21, 2013
Assignee:
The Scripps Research Institute
Inventors:
Peter Kuhn, John Ho Griffin, Kelly Bethel, Dena Marrinucci
Abstract: The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.
Abstract: The present invention provides a family of dark quenchers, termed Black Hole Quenchers (“BHQs”), that are efficient quenchers of excited state energy but which are themselves substantially non-fluorescent. Also provided are methods of using the BHQs, probes incorporating the BHQs and methods of using the probes.
Type:
Grant
Filed:
August 25, 2009
Date of Patent:
May 14, 2013
Assignee:
Biosearch Technologies, Inc.
Inventors:
Ronald M. Cook, Matt Lyttle, Daren Dick
Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated GAD autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated GAD autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated GAD autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.
Type:
Application
Filed:
July 14, 2011
Publication date:
May 9, 2013
Applicant:
Technion Research & Development Foundation LTD
Abstract: A method, apparatus and system that employs particles, e.g., nanoparticles, and an electric or electro-magnetic field, to cause electroporation in target cells at reduced fields. Electroporation may be irreversible, leading to targeted cell death, or reversible, allowing species to be introduced into the target cell. The method introduces a particle to a position adjacent to the cell membrane of a target cell and exposes the target cell to a transient electromagnetic field for a time interval to cause targeted electroporation. A smaller electric field is applied, thereby surmounting similar methods. The particle enhances the effect of the electric field in its immediate vicinity, so reducing the field strength needed to achieve electroporation and thereby reducing the risk of damage to cells through high field exposure. Electroporation can be targeted to a subset of target cells by targeting the particles to surface markers on the target cell membrane.
Type:
Application
Filed:
October 27, 2011
Publication date:
May 2, 2013
Inventors:
Soiwisa Soikum, Lars Thomsen, John Robert Dodgson
Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described.
Type:
Grant
Filed:
June 3, 1998
Date of Patent:
April 30, 2013
Assignee:
Aberystwyth University
Inventors:
Galina V Mukamolova, Arseny S Kaprelyants, Danielle I Young, Douglas B Kell, Michael Young
Abstract: This invention provides a immunochromatography detection device that can detect PBP2? produced specifically by a bacterium of multidrug-resistant staphylococcus with high sensitivity in a simple and rapid manner via immunochromatography detection to determine infection with multidrug-resistant staphylococcus, a diagnostic method using such detection device, and a diagnostic kit comprising such detection device.
Abstract: The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules.
Abstract: Multi-leg luminescent nanoparticles (“MLN's”) that can be paired to other MLN's as well s biological molecules to film branched multi-leg luminescent nanoparticles (“BMLN's) that can be used in biological multiplexing applications, imaging applications, biological detection applications and other biological applications.
Abstract: The present invention relates to methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies, immunoglobulin G class 3 (IgG3) antibodies with an improved therapeutic efficacy and the use thereof as a medicament, in particularly a medicament for immunotherapy. Specifically, the present invention relates to methods for increasing the therapeutic efficacy of an immunoglobulin G class 3 (IgG3) antibody comprising providing a mutated immunoglobulin G class 3 (IgG3) antibody, wherein the mutation, as compared to the parent immunoglobulin G class 3 (IgG3) antibody, comprises a replacement of the amino acid arginine (R) at position 435 in the CH3 domain with the amino acid histidine (H), and antibodies obtained by the present methods and their use as a medicament.
Type:
Grant
Filed:
January 18, 2008
Date of Patent:
April 23, 2013
Assignee:
Stichting Sanquin Bloedvoorziening
Inventors:
Gestur Vidarsson, Catherine E. Van der Schoot
Abstract: A system and method for GPCR signaling pathway analysis and elucidation using a biosensor, a live-cell, and a pathway active compound, as defined herein.
Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
April 23, 2013
Assignee:
Exelixis, Inc.
Inventors:
Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang
Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
Type:
Grant
Filed:
June 5, 2006
Date of Patent:
April 23, 2013
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform Al—B of Heterogeneous nuclear ribonucleoprotein Al, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9.
Type:
Application
Filed:
January 17, 2012
Publication date:
April 18, 2013
Applicant:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.
Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.
Type:
Grant
Filed:
May 27, 2009
Date of Patent:
April 16, 2013
Assignee:
Kyowa Hakko Kirin Co., Ltd.
Inventors:
Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song
Abstract: An acoustic wave biosensor comprises a plurality of spaced apart electrodes disposed on a substrate of piezoelectric material and having a biolayer matched to a specific type of autoinducer signaling molecule to be detected. The biolayer comprises a layer of heterobifunctional molecules disposed on the electrodes and on the piezoelectric material between the electrodes, and a plurality of bioreceptor molecules which bind exclusively with the specific type of autoinducer signaling molecule to be detected. The bioreceptor molecules are supported by the layer of heterobifunctional molecules, and a hydrogel layer surrounds the bioreceptor molecules to support a three-dimensional structure thereof. The bioreceptor molecules can bind with the specific type of autoinducer signaling molecule to be detected, and the biolayer is reactive thereto such that corresponding autoinducer signaling molecules bind to the biolayer and detectably vary acoustic characteristics of the acoustic wave biosensor.
Type:
Grant
Filed:
December 11, 2009
Date of Patent:
April 16, 2013
Assignee:
P.J. Edmonson Ltd.
Inventors:
Peter J. Edmonson, William D. Hunt, Desmond D. Stubbs
Abstract: The present application relates to the isolation and analysis of populations of microvesicles, such as populations of microvesicles that are shed by tumor cells and contain the protein ARF6. Invasive microvesicles from tumor cells contain a variety of specific proteins, including ARF6.
Type:
Grant
Filed:
November 9, 2010
Date of Patent:
April 16, 2013
Assignee:
University of Notre Dame
Inventors:
Crislyn D'Souza-Schorey, James W. Clancy, Vandhana Muralidharan-Chari
Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
April 16, 2013
Assignee:
University of Florida Research Foundation
Inventors:
Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
Type:
Grant
Filed:
January 30, 2012
Date of Patent:
April 16, 2013
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Gene Kinney, William R. Strohl, Zhiqiang An
Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.
Abstract: A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed.
Abstract: A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.
Abstract: An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte.
Abstract: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.
Type:
Application
Filed:
September 25, 2011
Publication date:
March 28, 2013
Applicant:
CHANG GUNG MEDICAL FOUNDATION, LINKOU BRANCH
Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.
Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS.
Abstract: Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids.
Type:
Grant
Filed:
February 2, 2009
Date of Patent:
March 26, 2013
Assignee:
Sanofi Pasteur Limited
Inventors:
Martina Ochs-Onolemhemhen, Roger Brookes, Claire-Anne Siegrist
Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
Type:
Grant
Filed:
May 13, 2009
Date of Patent:
March 26, 2013
Assignee:
Metheresis Translational Research SA
Inventors:
Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
Abstract: The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. The molecules can be directly coated on the surface or coated on nanoparticles that are adhered to the surface. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.
Type:
Grant
Filed:
November 20, 2009
Date of Patent:
March 19, 2013
Assignee:
The University of Rochester
Inventors:
Michael R. King, David G. Foster, Woojin Han, Bryce A. Allio
Abstract: The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.